Weekly Research Analysts’ Ratings Changes for Exelixis (EXEL)

Several analysts have recently updated their ratings and price targets for Exelixis (NASDAQ: EXEL):

  • 11/13/2026 – Exelixis had its price target lowered by Morgan Stanley from $60.00 to $57.00. They now have an “equal weight” rating on the stock.
  • 11/9/2026 – Exelixis was upgraded by Wall Street Zen from “buy” to “strong-buy”.
  • 11/5/2026 – Exelixis had its price target raised by Leerink Partners from $55.00 to $58.00. They now have a “market perform” rating on the stock.
  • 11/2/2026 – Exelixis had its price target raised by HC Wainwright from $56.00 to $78.00. They now have a “buy” rating on the stock.
  • 11/1/2026 – Exelixis was downgraded by Wall Street Zen from “strong-buy” to “buy”.
  • 10/30/2026 – Exelixis had its “market perform” rating reaffirmed by BMO Capital Markets. They now have a $60.00 price target on the stock.
  • 10/30/2026 – Exelixis had its price target raised by TD Cowen from $55.00 to $76.00. They now have a “buy” rating on the stock.
  • 10/30/2026 – Exelixis had its price target raised by Morgan Stanley from $53.00 to $60.00. They now have an “equal weight” rating on the stock.
  • 10/30/2026 – Exelixis had its price target raised by Truist Financial from $54.00 to $60.00. They now have a “hold” rating on the stock.
  • 10/30/2026 – Exelixis had its price target raised by Royal Bank Of Canada from $51.00 to $58.00. They now have a “sector perform” rating on the stock.
  • 10/30/2026 – Exelixis had its price target raised by Barclays from $49.00 to $54.00. They now have an “equal weight” rating on the stock.
  • 10/24/2026 – Exelixis was upgraded by Wall Street Zen from “buy” to “strong-buy”.
  • 10/19/2026 – Exelixis had its “market outperform” rating reaffirmed by Citigroup.
  • 10/19/2026 – Exelixis had its price target raised by Citizens Jmp from $55.00 to $65.00. They now have a “market outperform” rating on the stock.
  • 10/9/2026 – Exelixis had its price target raised by Royal Bank Of Canada from $45.00 to $51.00. They now have a “sector perform” rating on the stock.
  • 10/8/2026 – Exelixis was upgraded by Weiss Ratings from “buy (a-)” to “buy (a)”.
  • 10/8/2026 – Exelixis had its price target lowered by Royal Bank Of Canada from $46.00 to $45.00. They now have a “sector perform” rating on the stock.
  • 10/7/2026 – Exelixis had its price target raised by Truist Financial from $52.00 to $54.00. They now have a “hold” rating on the stock.

Exelixis Stock Performance

Shares of NASDAQ EXEL traded down $0.21 during midday trading on Wednesday, reaching $68.29. 1,818,389 shares of the company traded hands, compared to its average volume of 2,626,316. The firm has a market cap of $16.66 billion, a PE ratio of 20.45, a PEG ratio of 1.73 and a beta of 0.45. The stock’s 50-day simple moving average is $62.66 and its 200-day simple moving average is $52.48. Exelixis, Inc. has a 12 month low of $39.71 and a 12 month high of $73.69.

Exelixis (NASDAQ:EXEL – Get Free Report) last announced its earnings results on Thursday, October 29th. The biotechnology company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.89 by $0.05. The company had revenue of $658.70 million for the quarter, compared to analysts’ expectations of $646.51 million. Exelixis had a return on equity of 45.54% and a net margin of 35.45%. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.78 earnings per share. On average, equities research analysts expect that Exelixis, Inc. will post 3.42 EPS for the current year.

Exelixis, Inc. is a biotechnology company focused on discovering, developing and commercializing medicines for cancer. Founded in 1994 and headquartered in Alameda, California, the company has built its business around oncology treatments and continues to advance a pipeline of potential cancer therapies. Its principal marketed medicine is cabozantinib, sold in the United States as Cabometyx and Cometriq. Cabometyx is used to treat certain patients with advanced kidney, liver and thyroid cancers, while Cometriq is used for medullary thyroid cancer.

Read More

Receive News & Ratings for Exelixis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc and related companies with MarketBeat.com's FREE daily email newsletter.